Development and characterization of anti-glycopeptide monoclonal antibodies against human podoplanin, using glycan-deficient cell lines generated by CRISPR/Cas9 and TALEN.
about
Antitumor activity of chLpMab-2, a human-mouse chimeric cancer-specific antihuman podoplanin antibody, via antibody-dependent cellular cytotoxicity.Plasma soluble podoplanin is a novel marker for the diagnosis of tumor occurrence and metastasis.C-Type Lectin-Like Receptors As Emerging Orchestrators of Sterile Inflammation Represent Potential Therapeutic Targets.
P2860
Q54946843-B0CB0B4B-EEC8-47BA-9D10-2E74DF189507Q54946844-0108C1BD-A312-41F2-8555-1D1F1B427DBCQ54946845-4680E683-853A-4B83-BF91-8ACB37733C98Q54946846-652FBC09-8C91-4401-A816-86AEF3FF56EAQ54946847-DEF296D1-69FA-4BD4-925C-C7C5EFE99DF2Q54946849-E5B3BE56-86B2-4D32-B859-EE8B2A102964Q54946850-E6D8B121-A650-4DF8-9C90-950871A5D217
P1343
Development and characterization of anti-glycopeptide monoclonal antibodies against human podoplanin, using glycan-deficient cell lines generated by CRISPR/Cas9 and TALEN.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 19 January 2017
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Development and characterizati ...... ated by CRISPR/Cas9 and TALEN.
@en
Development and characterizati ...... ated by CRISPR/Cas9 and TALEN.
@nl
type
label
Development and characterizati ...... ated by CRISPR/Cas9 and TALEN.
@en
Development and characterizati ...... ated by CRISPR/Cas9 and TALEN.
@nl
prefLabel
Development and characterizati ...... ated by CRISPR/Cas9 and TALEN.
@en
Development and characterizati ...... ated by CRISPR/Cas9 and TALEN.
@nl
P2093
P2860
P4510
P356
P1433
P1476
Development and characterizati ...... ated by CRISPR/Cas9 and TALEN.
@en
P2093
Hiroyoshi Suzuki
Hiroyuki Harada
Michiaki Takagi
Mika K Kaneko
Ryusuke Honma
Satoshi Ogasawara
Shinji Abe
Takuro Nakamura
Yasuhiko Nishioka
Yuki Fujii
P2860
P304
P356
10.1002/CAM4.954
P407
P577
2017-01-19T00:00:00Z